pipeline
Pipeline

Best-in-class and First-in-Class small molecule therapeutics.

Program

Indication

1

2

3

4

5

6

Anti-viral

ZX-7101A PA inhibitor

Flu

ZX-7101A

ZX-7101A potently inhibits cap-dependent endonuclease (CEN) in the PA proteins of influenza A and B viruses. Its pharmacological property is suitable for a single dose to treat and prevent influenza A and B virus infections.

In preclinical studies, ZX-7101A demonstrated superior efficacy against anti-influenza virus over Oseltamivir, and comparable efficacy with Xofluza. Not like Xofluza , Not like Xofluza , ZX-7101A showed no food effect on oral bioavailability, and potentially has better safety and efficacy in the clinic.

ZX-9010 Broad spectrum
Anti-viral agent

Infection

Oncology

ZX-101A PI3Kδ/γ inhibitor

HemOnc
Solid Tumor

ZX-101A

ZX-101A is a next-generation of PI3Kδ/γ inhibitor with improved therapeutic window in pre-clinical models. ZX-101A doesn’t carry the purine motif common in Idelalisib and Duvelisib and minimize the drug-drug interaction potential in combination therapies or in use with concomitant medications. Dual inhibition of PI3Kδ and PI3Kγ by ZX-101A as the treatment of hematologic malignancies may synergistically exert through directly inhibiting PI3K signaling in malignant lymphocytes and enhancing anti-tumor immunity. ZX-101A has the potential to be the best-in-class medicine for blood cancers as well as the first-in-class immune-oncology treatment to certain solid tumors.

ZX-101A is currently at the Phase I clinical development (ZX-101A-101 Study) in US. ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A administered orally (PO) once daily (QD) in 28-day cycles in patients with relapsed/resistant or refractory advanced hematologic malignancies. 

ZX-4081PI3Kγ inhibitor

Solid Tumor
Inflammation

ZX-4081

PI3Kγ is a molecular switch that controls immune suppression and activates integrin α4 and promotes immune suppressive myeloid polarization during tumor progression. It was demonstrated that inhibition of PI3Kγ overcomes resistance to checkpoint blockade therapy.

ZX-4081 is the most selective and potent PI3Kγ inhibitor up to date. In preclinical studies, it showed favorable pharmacokinetic profile and efficacy was confirmed in solid tumor models. ZX-4081 is on the way to become best-in-class PI3Kγ inhibitor for the treatment of solid tumors, either as single agent or combination with other anticancer agents.

ZX-5000 Undisclosed IO target

Solid Tumor

ZX-8000Undisclosed IO target

Solid Tumor

Remarks
1:Discovery  2:Pre-clinical  3:Phase I    4:Phase II    5:Phase III       6:Marketed